Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 25kWORD 21k
28 October 2019
Answer given by Mr Moedas on behalf of the European Commission
Question reference: E-002599/2019

The Commission recognises the importance of research on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Under Horizon 2020, the EU Framework Programme for Research and Innovation (2014-2020)(1), the project Help4Me(2), funded via the SME Instrument, has worked on developing GutMagnific™, a probiotic designed to correct the gut microflora imbalance — linked to CFS symptoms. This innovative product could represent a life-changing promise to severely underserved population of CFS patients. Moreover, Horizon 2020 funds GLORIA(3), a project investigating the pathophysiology of chronic pain conditions, and the RTCure(4) project that aims at improving diagnostics and treatment of the rheumatic and other autoimmune diseases largely associated with fatigue and pain.

Horizon 2020 strategically supports scientific excellence using a variety of funding schemes, including bottom-up approaches, and continues to provide opportunities for research funding on ME/CFS. The Commission has proposed that Horizon Europe(5), building upon Horizon 2020, continues to support research in a flexible manner to improve the health of the European citizens and to provide further opportunities for research in ME/CFS.

(2)Evidence-based probiotic for Chronic Fatigue Syndrome — https://cordis.europa.eu/project/rcn/223054/factsheet/en
(3)Understanding chronic pain and new druggable targets: Focus on glial-opioid receptor interface — https://cordis.europa.eu/project/rcn/110940/factsheet/en
(4)Rheuma Tolerance for Cure — https://cordis.europa.eu/project/rcn/211964/factsheet/en

Last updated: 30 October 2019Legal notice - Privacy policy